Normal view

Received — 10 September 2026 ⏭ Journals

Nature - Issue - nature.com science feeds
TRI-611, a selective, brain-penetrant molecular glue degrader of ALK Andrew R. Conery · Daniel S. La · Artyom A. Alekseyenko · David Marcoux · Aaron G. Bart · Matt L. Harlow · Patrick R. Arsenault · Nico R. Cantone · Rebecca L. Casaubon · Alexander Constan · Hari B. Kamadurai · Aravind Prasad Medikonda · Duncan E. Nunes · Hannah Szeto · Tim J. Wigle · Maolin Yu · Aleksandra Zagulyaeva · Christine M. Zarate · Lauren Highfield · Nobuyuki Kondo · Aaron N. Hata · Kenneth Ngo · Jisu Lee · Prafulla C. Gokhale · Caroline Germa · Kathleen I. Seyb · Patrick Trojer · Vito J. Palombella
Nature, Published online: 09 September 2026; doi:10.1038/s41586-026-10998-3TRI-611 induces the degradation of ALK fusion proteins via a previously undescribed CRBN recruitment motif, and its preclinical anti-tumour activity highlights TRI-611 as a potential new way of treating ALK-positive non-small-cell lung cancer.
9 September 2026 at 08:00

TRI-611, a selective, brain-penetrant molecular glue degrader of ALK

Nature - Issue - nature.com science feeds

By: Andrew R. Conery · Daniel S. La · Artyom A. Alekseyenko · David Marcoux · Aaron G. Bart · Matt L. Harlow · Patrick R. Arsenault · Nico R. Cantone · Rebecca L. Casaubon · Alexander Constan · Hari B. Kamadurai · Aravind Prasad Medikonda · Duncan E. Nunes · Hannah Szeto · Tim J. Wigle · Maolin Yu · Aleksandra Zagulyaeva · Christine M. Zarate · Lauren Highfield · Nobuyuki Kondo · Aaron N. Hata · Kenneth Ngo · Jisu Lee · Prafulla C. Gokhale · Caroline Germa · Kathleen I. Seyb · Patrick Trojer · Vito J. Palombella

9 September 2026 at 08:00

Nature, Published online: 09 September 2026; doi:10.1038/s41586-026-10998-3

TRI-611 induces the degradation of ALK fusion proteins via a previously undescribed CRBN recruitment motif, and its preclinical anti-tumour activity highlights TRI-611 as a potential new way of treating ALK-positive non-small-cell lung cancer.

Received — 27 May 2026 ⏭ Journals

Nature Medicine
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial Priscilla Merriam · James J. Morrow · Emanuele Mazzola · Nicole L. Solimini · Prafulla C. Gokhale · Ping Chi · Alice P. Chen · Mark Agulnik · Melissa Burgess · Scott M. Schuetze · Neeta Somaiah · Brian A. Van Tine · Seth M. Pollack · Gabriel Tinoco · Jonathan Trent · Breelyn A. Wilky · Nicola Bothwick · Benjamin K. Eschle · Vivian Nguyen · Jan H. Beumer · Noushin Rastkari · Shahanawaz Jiwani · Peter I-Fan Wu · Lorraine Pelosof · Matthew L. Hemming · Geoffrey I. Shapiro · George Demetri · Bradley Bernstein · Suzanne George
Nature Medicine, Published online: 26 May 2026; doi:10.1038/s41591-026-04376-9In a multicenter phase 2 trial, the fibroblast growth factor receptor inhibitor rogaratinib showed encouraging clinical efficacy in patients with succinate dehydrogenase-deficient gastrointestinal stromal tumors, suggesting a potential new treatment option for this patient population and demonstrating that an epigenetic mechanism of oncogene activation can be successfully targeted with a tyrosine kinase inhibitor.
26 May 2026 at 08:00

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial

Nature Medicine

By: Priscilla Merriam · James J. Morrow · Emanuele Mazzola · Nicole L. Solimini · Prafulla C. Gokhale · Ping Chi · Alice P. Chen · Mark Agulnik · Melissa Burgess · Scott M. Schuetze · Neeta Somaiah · Brian A. Van Tine · Seth M. Pollack · Gabriel Tinoco · Jonathan Trent · Breelyn A. Wilky · Nicola Bothwick · Benjamin K. Eschle · Vivian Nguyen · Jan H. Beumer · Noushin Rastkari · Shahanawaz Jiwani · Peter I-Fan Wu · Lorraine Pelosof · Matthew L. Hemming · Geoffrey I. Shapiro · George Demetri · Bradley Bernstein · Suzanne George

26 May 2026 at 08:00

Nature Medicine, Published online: 26 May 2026; doi:10.1038/s41591-026-04376-9

In a multicenter phase 2 trial, the fibroblast growth factor receptor inhibitor rogaratinib showed encouraging clinical efficacy in patients with succinate dehydrogenase-deficient gastrointestinal stromal tumors, suggesting a potential new treatment option for this patient population and demonstrating that an epigenetic mechanism of oncogene activation can be successfully targeted with a tyrosine kinase inhibitor.